Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Respiratory Research

Fig. 2

From: A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial

Fig. 2

In the per-protocol population, SB010 led to a statistically significant reduction of the relative sputum eosinophils [% non-squamous cells], while placebo treatment did not change sputum eosinophil count (a). Comparing the deltas, no statistically significant difference was found (b). Data are displayed as mean ± standard error of the mean (SEM). P values were calculated by the two-sided Wilcoxon signed rank test for pre/post differences and the exact Wilcoxon two-sample test for the comparison of the deltas

Back to article page